Field of the Invention The present invention relates to a novel method of prevention or treatment of diseases where signal transduction pathways mediated by erbB-2 tyrosine kinase play a significant role. Examples thereof include abnormal cell proliferation, including cancer, particularly, breast cancer.

Background of the Invention For mammalian cells to survive, they must be able to respond rapidly to changes in their environment. Furthermore, for cells to reproduce and carry out other cooperative functions, they must be able to communicate efficiently with each other.

Cells most frequently adapt to their environment and communicate with one another by means of chemical signals. An important feature of these signaling mechanisms is that in almost all cases a cell is able to detect a chemical signal without it being necessary for the chemical messenger itself to enter the cell. This permits the cell to maintain the homeostasis of its internal environment, thereby permitting the cell to respond to its external environment without being adversely affected by it.

These sensing functions are carried out by a variety of receptors, which are dispersed on the outer surface of the cell and function as"molecular antennae." These receptors detect an incoming messenger and activate a signal pathway that ultimately regulates a cellular process such as secretion, contraction, metabolism or growth.

In the cell's cellular plasma membrane, transduction mechanisms translate external signals into internal signals, which are then carried throughout the interior of the cell by chemicals known as"second messengers." In molecular terms, the process depends on a series of proteins within the cellular plasma membrane, each of which transmits information by inducing a

conformational change in the protein next in line. At some point, the information is assigned to small molecules or even to ions within the cell's cytoplasm, which serve as the above-mentioned second messengers. The diffusion of the second messengers enables a signal to propagate rapidly throughout the cell.

Abnormal cell signaling has been associated with cancer diseases. Cell signaling plays a crucial role in cell growth, proliferation and differentiation. Thus, when normal cell signaling pathways are altered, uncontrolled cell growth, proliferation and/or differentiation can take place, leading to the formation and propagation of cancer.

Cancer is the leading cause of death, second only to heart disease in both men and women. Breast cancer is the most common tumor in women, representing 32% of all new cancer cases and causing 18% of cancer-related deaths of women in the United States. In the fight against cancer, numerous techniques have been developed and are the subject of current research to understand the nature and cause of the disease, and to provide techniques for the control or cure thereof.

One promising avenue for the development of cancer treatments is based on blocking abnormal cell signaling pathways. Particular efforts are directed to the elucidation and regulation of the activity of receptor and trans-membrane proteins.

The human epidermal growth factor (EGF) is a six kilodalton (kDa), 53 amino acid, single-chain polypeptide which exerts its biological effect by binding to a specific 170 kDa cell membrane receptor (EGF-Rc). The human EGF-Rc consists of an extracellular domain with a high cysteine content and N-linked glycosylation, a single transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity.

Many types of cancer display enhanced EGF-Rc expression on their cell surface membranes. Enhanced expression of the EGF-Rc can increase signalling via receptor-mediator pathways which lead to pleiotropic biological effects including excessive proliferation and metastasis. Examples include prostate cancer, breast cancer, lung cancer, head and neck cancer, bladder cancer, melanoma, and brain tumors.

In breast cancer, expression of the EGF-Rc is a significant and independent indicator for recurrence and poor relapse-free survival. The epidermal growth factor

receptor (EGF-Rc) of cancer cells therefore represents a potential target for biotherapy.

EGFR and its physiologic ligands, epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha), play a prominent role in the growth regulation of many normal and malignant cell types. One role the EGF receptor system may play in the oncogenic growth of cells is through autocrine-stimulated growth. Cells which express EGFR and secrete EGF and/or TGFalpha can stimulate their own growth, thereby creating a cancerous condition.

An autocrine growth stimulatory pathway analogous with that proposed for epidermal growth factor receptor and its ligands may also be employed by a growing list of oncogene encoded transmembrane proteins that have a structure reminiscent of that of the growth factor receptors.

The HER-2/neu or c-erbB-2 oncogene belongs to the erbB-like oncogene group, and is related to, but distinct from EGFR. The ErbB-2 gene encodes a 185 kD transmembrane glycoprotein that has partial homology with other members of the EGFR family. The expressed protein has been suggested to be a growth factor receptor due to its structural homology with EGFR. However, known EGFR ligands, such as EGF or TGF. alpha do not bind to p185-erbB-2.

The erbB-2 oncogene has been demonstrated to be implicated in a number of human adenocarcinomas leading to elevated levels of expression of the p 185 protein product. For example, the erbB-2 oncogene has been found to be amplified in breast, ovarian, gastric and even lung adenocarcinomas. Furthermore, the amplification of the c-erbB-2 oncogene has been found in many cases to be a significant, if not the most significant, predictor of both overall survival time and time to relapse in patients suffering from such forms of cancer. Carcinoma of the breast and ovary account for approximately one-third of all cancers occurring in women and together are responsible for approximately one-fourth of cancer-related deaths in females.

Significantly, the c-erbB-2 oncogene has been found to be amplified in 25 to 30% of human primary breast cancers and it has been associated with a high risk of relapse and death. In breast cancers with erbB-2 overexpression abnormal cell proliferation is believed to be caused by extremely high tyrosine kinase activity and the resulting high level of signal transduction.

Overexpression of HER-2 has also been found to be associated with increased resistance to chemotherapy or patients with elevated levels of HER-2 respond poorly to many drugs. It is believed that decreasing the levels of HER-2 will allow chemotherapeutic drugs to be more effective. Therefore, therapies targeted at erbB-2 have the great therapeutic potential for the treatment of breast cancers.

In view of the above, the development of new and potent anti-breast cancer drugs and the design of treatment protocols directed at the regulation of erbB-2 activity is an exceptional focal point for research in the modern therapy of breast cancer. Drug targeting is a particularly attractive approach for killing malignant cells, when leaving normal tissue unharmed is achieved.

ErbB-2 is a clinically proven therapeutic target for breast cancer. Indeed, the recently completed phase M clinical trial of anti-Her2 Herceptin provide evidence that systemic administration of Herceptin, alone and in combination with cytotoxic chemotherapy in patients with erbB-2 overexpressing primary tumors, can increase the time to recurrence and overall response rates in metastatic breast cancer.

Herceptin is recognized as the first in what promises to-be a wave of therapies attacking cancer at its genetic roots.

Certain limitations are associated with large molecule strategies, including poor delivery, poor in vivo stability, possible immune response and high cost.

Accordingly, it is highly desirable to provide therapies based on small molecules targeted at interfering with erbB receptor-mediated signal transduction pathways (including erbB-2, erbB-3 and erbB-4). Compared to therapies based on large drug molecules, such as therapeutic antibodies, small molecule drug therapies have a number of advantages, including good oral availability and low cost.

A number of criteria should be considered in the development of small molecule erbB-2 kinase inhibitors, including good potency, selectivity, cell permeability, bioavailability, appropriate pharmacokinetics and non-toxicity.

In breast cancers with erbB-2 overexpression, abnormal cell proliferation is caused by the extremely high tyrosine kinase activity and resulting high level of signal transduction. Drugs blocking this extremely high erbB-2 tyrosine kinase activity could have the potential to shut down signaling pathways mediated by erbB- 2. Thus, erbB-2 kinase inhibitors that are capable of entering the cell, blocking

tyrosine kinase activity and shutting down the signal transduction pathway mediated by erbB-2 may be used as potential therapeutic agents for the treatment of breast cancer. Furthermore, it has been shown that tyrosine kinase inhibitors synergize with antibodies to EGFR to inhibit the growth of aquamous cell carcinoma in vivo. Thus, a specific erbB-2 kinase inhibitor may also have synergistic effects with Herceptin in the treatment of breast cancer.

The development of small molecule kinase inhibitors of the EGFR family of receptors tyrosine kinases has been so far focused on EGFR itself. Very potent and selective EGFR small molecule kinase inhibitors have been reported and some EGFR small molecule kinase inhibitors have advanced to phase I/II clinical trials for the treatment of certain cancer forms. To date, very few kinase inhibitors selective for erbB-2 were reported.

Therefore, it would be greatly beneficial if new therapies could be designed based on identified existing compounds, rationally modified compounds and/or de novo designed compounds which are active as erbB-2 kinase inhibitors. In particular, it would be helpful if therapies based on compounds having improved selectivity, solubility and stability could be obtained.

Summary and Objects of the Invention It is an object of the invention to provide novel therapies based on inhibiting in vivo the erbB-2 kinase signaling pathway.

It is a more specific object of the invention to provide novel therapies that result in the inhibition of cell proliferation and/or differentiation and/or the promotion of cell apoptosis comprising the administration of a compound that erbB-2 kinase related cell growth signaling.

It is an even more specific object of the invention to provide novel therapies that result in the inhibition of cell proliferation and/or differentiation and/or promotion of cell apoptosis by the administration of a compound having formulae (I) to (V):

Formula I Formula II Formula in Formula IV Formula V In a preferred embodiment, such therapies will comprise treatment of cancer and other neoplastic conditions.

Brief Description of the Drawings Figures illustrate some of the compounds of the invention, methods for identifying those compounds and results of in vitro and in vivo biological test demonstrating the activity of illustrative compounds according to the invention.

Detailed Description of the Invention In cells transformed By erbB-2 overexpression, therapeutic agents inhibiting erbB-2 kinase activity can interrupt the flow of signal transduction mediated by erbB- 2 receptor to the ras pathway and may result in the reversal of the cancer phenotype.

Thus, one object of the invention is to provide therapies based on inhibition erbB-2 kinase activity.

The present invention provides therapies based on compounds capable of interfering with erbB-2 kinase activity. In one aspect, the invention provides therapies based on existing compounds which are identified through computational modeling as inhibitors of erbB-2 kinase activity. In another aspect, the invention provides novel compounds which are designed by rational design modification or existing compounds or de novo to provide high activity and selectivity and therapies based on these compounds.

In a first aspect, the present invention provides novel therapies based on existing compounds which are identified as potent and selective small molecule inhibitors of erbB-2 kinase. The compounds are identified through structure-based three-dimensional (3D) database searching. The compounds identified through database searching are processed through biological tests to identify one or more lead compounds for clinical testing and/or rational drug design refinement.

Computationally predicting a compound's binding affinity to a host protein involves utilizing the three dimensional (3-D) structures of the host protein and the compound. The 3-D structure of the compound is obtained from a database of chemical compounds. The 3-D structure of the host protein can also be obtained from a protein database.

The invention provides potent and erbB-2 specific kinase inhibitors through a structure-based drug discovery approach. The methodology employed in the discovery of erbB-2 kinase inhibitors is disclosed in U. S. Patent Application No.

09/301,339, filed on April 29,1999, the contents of which are hereby incorporated by reference in their entirety. A flow chart for the methodology is shown in Figure 1.

Briefly, in structure-based 3D-database searching for drug discovery, once the 3D structure of the target molecule (a receptor or an enzyme) is determined, large chemical databases containing the 3D structures of hundreds of thousands of structurally diverse synthetic compounds and natural products are searched through computerized molecular docking to identify small molecules that can interact effectively with the target or host molecule. In spite of the massive increase in the number of biological molecules whose 3-D structure has been elucidated, the majority of proteins of known primary structure (amino acid sequence) do not have a known tertiary (or 3-D) structure.

For drug design involving target proteins of unknown tertiary structure, a model structure can be constructed based on the known tertiary structure of a protein which is homologous to the target protein. The structure of the homologous protein is used to construct a template structure of all or part of the target protein. The structure obtained through homology modeling provides a working structure for further refinement. The working structure for the protein not having a known structure is obtained by refining the template structure.

In forming a template 3-D structure of the host protein, each atom of the backbone of the target protein is assigned a position corresponding to the position of the equivalent backbone atom in the homologous protein. Similarly, each atom of a side chain of the target protein having an equivalent side chain in the homologous protein is assigned the position corresponding to the position of the atom in the equivalent side chain of the homologous protein. The atom positions of a side chain not having an equivalent in the homologous protein are determined by constructing the side chain according to preferred internal coordinates and attaching the side chain to the backbone of the host protein.

The template structure thus obtained is refined by minimizing the internal energy of the template protein. During the refinement, the positions of the atoms of the side chains having no equivalents in the homologous protein are adjusted while keeping the rest of the atoms of the template protein in a fixed position. This allows the atoms of the constructed side chains to adapt their positions to the part of the template structure determined by homology. The full template structure is then minimized (relaxed) by allowing all the atoms to move. Relaxing the template 3-D structure of the protein eliminates unfavorable contacts between the atoms of the protein and reduces the strain in the template 3-D structure.

Based on the refined structure of the target protein, a host-guest complex is formed by disposing a compound from a compound database in a receptor site of the protein. The structure of the host-guest complex is defined by the position occupied by each atom in the complex in a three dimensional referential.

A geometry-fit group is formed by selecting the compounds which can be disposed in the target binding site without significant unfavorable overlap with the atoms of the protein. For each compound in the geometry fit group, a predicted

binding affinity to the receptor site of the host protein is determined by minimizing an energy function describing the interactions between the atoms of the compound and those of the protein. The minimization of the energy function is conducted by changing the position of the compound such that a guest-host complex structure corresponding to a minimum of the energy function is obtained. The compounds having the most favorable energy interaction with the atoms of the binding site are identified for optional further processing, for example through display and visual inspection of compound protein complexes to identify the most promising compound candidates.

The displayed complexes are visually examined to form a group of candidate compounds for in vitro testing. For example, the complexes are inspected for visual determination of the quality of docking of the compound into the receptor site of the protein. Visual inspection provides an effective basis for identifying compounds for in vitro testing.

After putative binding compounds have been identified, the ability of such compounds to specifically bind to erbB-2 kinase is confirmed in vitro and/or in vivo.

The potency and selectivity of potential erbB-2 kinase inhibitors is evaluated in vitro with breast cancer cells overexpressing erbB-2 (MDA-453) or EGFR (MDA- 468), model cells (32D cells transfected with EGFR or erbB-2/erbB3, erbB-2/erbB-4, erbB-4), or NIH3T3 cells transfected with EGFR, EGFR/erbB-2 or erbB-2). Potent and selective inhibitors are tested further in their ability to inhibit colony-formation in soft-agarose. Compounds having good in vitro activity are tested in vitro. Tumor bearing mice are treated with therapy, based on the compounds and the effect on the tumor size is observed. Compounds showing effective tumor reduction are then used in clinical trial protocols.

Computational identification of compounds having potential erbB-2 kinase inhibitory activity To date, the experimental 3D structure (including the kinase domain) of either erbB-2 or EGFR has not been determined. However, the structures of the kinase domain of a number of other receptor tyrosine kinases have been determined through X-ray crystallography. The kinase domain of these receptor tyrosine kinases is

closely related to those of erbB-2 and EGFR, which provides an opportunity to model the 3D structure of the kinase domain of erbB-2 and EGFR using the homology modeling approach described above.

Protein kinases, including erbB-2 and EGFR, have an active and an inactive conformation. Inhibition of either of these two conformational states can lead to the inhibition of kinase activity.

The sequences (or primary structures) of erbB-2 and EGFR were obtained from the Protein Gene Bank. Templates for homology modeling were obtained by searching the Protein Databank. 3D structures of the receptors were built using the homology-modeling based on the X-ray structure of the active and inactive insulin receptor tyrosine kinase as a template to model the active and inactive conformation of the erbB-2 and EGFR kinase domains, respectively.

Insulin receptor tyrosine kinase domain has 35% identities, 52% similarities and 10% gaps when compared to that of erbB-2, and 35% identities, 52% similarities and 5% gaps when compared to that of EGFR.

In forming a template structure of the erbB-2 kinase receptor domain, each atom in the backbone of the erbB-2 kinase domain was assigned a position corresponding to the position of the equivalent atom in the 3-D structure of the insulin receptor kinase domain. Similarly, each atom of a side chain of the erbB-2 kinase domain having an equivalent side chain in the insulin receptor kinase domain was assigned a position corresponding to the position of the atom in the equivalent side chain of the insulin receptor kinase domain. The atoms of the side chains of the erbB- 2 kinase domain not having equivalents in the insulin receptor kinase domain were determined by positioning the side chain according to its position in the amino acid sequence of ErbB-2 kinase and refining the template structure thus obtained. The refined template structure was then relaxed to reduce the strains which may have been present in the refined template.

The backbone-3D structures of the activated insulin receptor tyrosine kinase domain and the corresponding model structures of erbB-2 and EGFR are shown in Figure 2.

The ATP binding site of the erbB-2 kinase domain from the refined structure (both the active and inactive conformation) was used as the target for structure-based database searching.

Database searching was conducted by processing two databases, the National Cancer Institute 3D-database (279,000 compounds) and the Available Chemical Database (250,000 compounds). Each compound in the databases was processed to identify compounds having a shape which is complementary to the shape of the erbB- 2 ATP binding site. For each compound, a rigid body docking minimum energy was evaluated and the compounds were ranked according to their rigid body docking energy. In this procedure each compound was rigidly docked into the modeled erbB- 2 ATP active site. That is, the compound was docked into the active site without changing the internal coordinates of the compound.

A geometry fit/rigid body docking group was formed by the top 20,000 compounds obtained through shape complementarity ranking. These compounds were further processed by evaluating their energetic binding affinity the ATP binding site of erbB-2 kinase. The compounds were processed through flexible docking processing. That is, the compounds were allowed to adjust their internal coordinates during docking thereby allowing for flexible docking. Flexible docking allowed a more accurate determination of the energy of interaction between each compound and the atoms forming the ATP active site.

The top 2,000 compounds according to the flexible docking energy ranking were further examined to eliminate highly charged compounds whose ability to enter the cell would be greatly hampered by their change. Of the 2000 compounds selected through flexible docking, 1000 compounds were selected for biological processing through in vitro and in vivo testing based on their net electrostatic change.

The potency and selectivity of potential erbB-2 kinase inhibitors was evaluated in vitro with breast cancer cells overexpressing erbB-2 (MDA-453) or EGFR (MDA-468) and model cells (32D cells transfected with EGFR or erbB- 2/erbB3, erbB-2/erbB-4, erbB-4, or NIH3T3 cells transfected with EGFR, EGFR/erbB-2 or erbB-2).

The compounds were also tested for inhibitory activities in phosphorylation, cell growth and MAP kinase. Selected compounds were further tested for their ability to inhibit colony-formation in soft-agarose.

Cell proliferation assays were also performed. A soluble tetrazolium/ formazan (XTT) assay was performed to directly measure the cell killing activity in a 96-well plate. The soft-agar colony formation assay was employed to directly measure the transforming ability of select compounds as this test provides data that has been shown to correlate well with in vivo tumorigenicity.

In order to show the presence of erbB receptors in the biological materials used in testing the compounds identified or designed according to the invention, a series of antibodies specific for each of the erbB receptors were tested for both western blotting and immunoprecipitation experiments. Those antibodies were utilized to screen the expression of erbB receptors by western blot analysis in various breast cell fines as well as others that over express the erbB receptors. Each receptor was detected with a specific antibody, e. g., EGFR was detected with mAb (UBI), erbB-2 was detected with mAb (Oncogene Sciences), erbB-3 was detected with mAb (Oncogene Sciences), and antiphosphotyrosine mAb (UBI) and visualized with ECL (Amersham). The results for these probing tests are summarized in Table I: Table I. Cell Line Origin of EGFR erbB-2 erbB-3 erbB-4 Autophos-Tumori- Cells phorylation at genicity p185 or p170 MDA-453 breast ++ +++ SKBr3 breast + ++++ ++ +/- +++ BT-474 breast +/-++++ +++ +++ ++++ + (E2) NMA-361 breast +++ ++ ++ +++ + (E2) MDA-468 breast ++++ + n. d. +++ + MDA-231 breast ++ +/-+ ++++ A431 epidermal +++++ + ++ +/- ++++ ++++ MDA-435 breast. n. d. - ++ -- ++++ MCF-7 breast +/-+ ++ + + (E2) N87 gastric - +++++ +++ ++++ +++ +++ SKOV3 ovarian +++++ +/-++ +++

Figure 3 illustrates in vitro testing using 32D model cells. There are two main advantages of the 32D model cell system. First, the 32D cells are devoid of many receptors, therefore, they provide almost zero background of receptor autophosphorylation or cross-talks between receptors. 32D cells from non- tumorigenic, murine hematopoietic cell lines are devoid of receptors for many growth factors (e. g., EGF, PDGF, erbB-21314. KGF, IL-2, CSF-1, Met, Kit, etc.). Second, when 32D cells are transfected with a particular growth factor receptor, dual mitogenic and signal transduction pathways are created for the same transfectants expressing that receptor. For instance, 32D cells transfected with erbB-4 will proliferate in the presence of either HRG or IL-3. This IL-3 dependence, however, can be bypassed by the stimulation of signal transduction pathways initiated by the expression of specific growth factor receptors and the addition of the appropriate ligand to the culture medium.

In investigating ligand-induced phosphorylation of the erbB-2 receptor, we employed the 32D cells transfected with a combination of erbB-2 and erbB-3, since there is no binding or activation of erbB-2 in single erbB-2 transfected 32D cells. In addition, the NIH 3T3 cells transfected with the chimeric EGFR/erbB-2 receptor were used to test ligand-induced erbB-2 phosphorylation. To investigate ligand-induced phosphorylation of the EGFR receptor, 32D and NIH3T3 cells transfected with EGFR were used.

To investigate the inhibition of autophosphorylation of the erbB-2 receptor kinase, 32D and NIH 3T3 cells transfected with mutant erbB-2, the neu oncogenes, which exhibit a high level of autophosphorylation as employed.

Furthermore, using 32D cells transfected with a single (EGFR, mutant erbB-2, erbB-4) or double receptors (EGFR/erbB-2, erbB-2/erbB-3, erbB-2/erbB-4, EGFR/erbB-3, EGFR/erbB-4), allowed for the determination of preferential inhibitory activity blocking the kinase activity associated with either the homodimers or the heterodimers. NIH3T3 and MCF-7 transfected with other receptor tyrosine kinases including FGFR, PDGFR, VEGFR or ras were employed to evaluate their selectivity over receptor kinases not related with the EGFR family.

141 of the compounds identified through computational processing were tested for their ability to inhibit phosphorylation in human breast cancer cell line

MDA-453 that overexpresses erbB-2 obtained by gene amplification. Ten compounds were found to inhibit >90% of the auto-phosphorylation activity of erbB- 2 at 100 M. The ten compounds were further tested in a dose-dependent phosphorylation assay both in an MDA-453 cell line, and an MDA-468 cell line. The latter overexpresses the EGFR receptor.

Of the ten compounds identified above, six compounds were found to have relative selectivity in inhibiting phosphorylation in MDA-453 cells over MDA-468 cells. One particular compound that was found to have excellent biological activity is B 17. Figure 4 (A) shows the structure of compound B 17 and Figure 4 (B) shows compound B 17 within the modeled active site of erbB-2 kinase.

Figure 5 (C) shows the irreversible inhibition obtained, by treating the cells with compound B17 for 30 min and washout for 8 hours, then assaying for tyrosine phospohrylation. As shown in Figures 5 (A) to 5 (C), lead compound B17 has excellent potency (ICso was estimated to be approximately 1-2 M) and does not inhibit the EGFR phosphorylation in up to 400 M. The results shown in Figure 5 (A) to 5 (C) show, unexpectedly that lead compound B17 has a selectivity more than 100- fold for erbB-2 over EGFR.

B 17 exposure did not affect the expression of erbB-2 or EGFR. Moreover, using P32 labeled ATP binding assay, we confirmed that B17 blocks the binding of ATP to erbB-2 but not to EGFR, suggesting that B17 is indeed an ATP competitive inhibitor.

In further probing the biological activity of B17, the NIH-3T3 cells that overexpress either EGFR, erbB-2 or-the chimeric EGFR (extracellular) and erbB-2 (intracellular) receptor through transfection were exposed to treatmetn with B17.

Both EGFR and chimeric EGFR/erbB-2 depend on the addition of EGF to induce phosphorylation. Overexpression of erbB-2 receptor resulted in a high level of auto- phosphorylation in these cells. As shown in Figure 6, lead compound B17 selectively inhibits the EGF-induced erbB-2 kinase activity in the EGFR/erbB-2 chimeric receptor of 3T3-EGFR/erbB-2 cells, but not the EGFR kinase activity in 3T3-EGFR cells. B17 also inhibits the autophosphorylation of erbB-2 in 3T3/erbB-2 cells.

To test if B 17 blocks the MAP kinase activity mediated by erbB-2, we tested the MAP kinase activity induced by Heregulin in MDA-453 and induced by EGF in

MDA-468. We found that the MAP kinase activity in MDA-453 was inhibited by B 17 with a potency similar to the inhibition of phosphorylation of erbB-2, while the MAP kinase activity in MDA-468 was not inhibited with concentrations of up to 400 M, indicating that B17 specifically inhibits the erbB-2 receptor mediated MAP kinase signaling pathway.

Furthermore, we tested the ability of B17 to inhibit cell growth using MDA- 453,3T3/erbB-2. MDA-468 and 3T3/EGFR. As shown in Figure 7, it was found that B17 exhibits an ICso < 0.625 M in MDA-453 and (3T3/erbB-2 data not shown), while only having 25% inhibition at 5 M in MDA-468 (Fig. 4) as shown in Figure 8 and in NIH3T3/EGFR (data not shown).

Figure 7 shows the in vivo inhibition of erbB-2 tyrosine phosphorylation in BT-474 cells, which also overexpress the erbB-2 as in MDA-453 cells, but are highly tumorigenic in nude mice. The figure shows that in tumor-bearing mice (BT-474), there is more than 70% (2/3) reduction in erbB-2 phosphorylation activity compared with the activity obtained for control untreated tumors. The activity of the B 17 compound in animal systems was further probed. Figure 8 shows that down-stream effector protein, MAP kinase phosphorylation is markedly reduced by in vivo treatment of B17 in tumor cells. As shown in Figure 8, no change in the expression level of Cerb-2 protein was observed in human breast carcinoma BT-974 cells 24 hours after intraperitonial injection 100mg/kg of B17.

Longterm in vivo efficacy investigations were conducted on mice treated with 100mg/kg of B17, by intraperitonial injection twice per week. As shown in Figure 9, the treatment produced about 28% reduction of tumor volume compared to controls at day 15.

The above results indicate that lead compound B17 is a fairly potent ATP competitive kinase inhibitor which selectively blocks the erbB-2 kinase activity, thereby shutting-down erbB-2 mediated signaling transduction pathway. When added directly to cells in culture, it was found that B17 inhibits cellular proliferation of erbB-2 overexpressing cells. In addition, we found that B17 is an irreversible inhibitor.

Based on the unexpected biological activity and selectivity found for the compound B17, the compound databases were further searched to identify analogs of

B 17 that may have even greater activity and/or selectivity in inhibiting erbB-2 activity. The search in the NCI database produced over 40 closely related analogues of lead compound B17.

The following is a table showing the chemical structure and activity of some of the analogues of B17 : Rotational drug design of erbB-2 kinase inhibitors In another aspect, the present invention provides novel compounds which are rationally designed to inhibit erbB-2 kinase activity. Rational design of the novel compounds is based on information relating to the binding site of the erbB-2 kinase protein. The structures of the protein and a lead compound is analyzed such that compound structures having possible activity in binding to the binding site are formulated.

The structure of the lead compounds is divided into design blocks the modification of which is probed for influence on the interactions between the lead compound and the active site. Compounds having different design block combinations are then synthesized and their activity in relation to the identified mechanism is tested. Such tests are conducted in vitro and/or in vivo, in the same manner described above for lead compound B 17. The information obtained through such tests is then incorporated in a new cycle of rational drug design. The design- synthesis-testing cycle is repeated until a lead compound having the desired properties is identified. The lead compound is then clinically tested.

As discussed above in connection with the modeling of the structure of the erbB-2 kinase domains, it has been found that erbB-2 and EGFR have a very similar ATP binding site as compared to other receptor kinases such as insulin receptor tyrosine kinase. However, the erbB-2 kinase domain has two distinctive residues (Cys805 and Ser753) located at the ends of the ATP binding site (Fig. 1). The Cys805 is common within the EGFR family but not shared by other receptor kinases.

Ser783 is unique to erbB-2 (EGFR has a Cys residue at this position).

The distinguishing structural features of the erbB2 receptor site were employed as a guide in rationally designing novel compounds having enhanced binding activity and selectivity towards the erbB-2 receptor. The structure of lead

compound B 17 was rationally modified to enhance the interactions between B17 and the Ser 780.

Based on the above computational modeling, database searching, rational drug design, in vitro and in vivo biological testing, the present inventors have discovered that compounds having the generic formula set forth below specifically interact with erbB-2 kinase molecules: Formula I Formula II Formula III Formula IV Formula V

Thus, the compounds produced according to the invention will be used to treat conditions wherein inhibition of erbB-2 kinase signaling is therapeutically beneficial.

This will include conditions that involve abnormal cell growth and/or differentiation such as cancers and other neoplastic conditions. Also, the subject compounds may be used to treat other conditions involving abnormal cell proliferation and/or differentiation such as dermatological conditions and disorders. Also, the subject compounds may be useful in treating inflammatory conditions such as arthritis, psoriasis, autoimmune disorders such as myasthenia gravis, lupus, multiple sclerosis, and others, and conditions involving abnormal platelet aggregation. The preferred indication is cancer, especially cancers involving over-expression of erbB-2 EGF and/or the PDGF receptor, cancers that express mutant ras, or cancers which comprise a Bcr/Abl translocation. Examples of cancers which may be treated according to the invention include breast colon, pancreatic, prostate, head and neck, gastric, renal, brain and CML.

The subject therapies will comprise administration of at least one compound according to the invention in an amount sufficient to elicit a therapeutic response, e. g., inhibition of tumor cell proliferation and/or differentiation and/or promotion of apoptosis.

The compound may be administered by any pharmaceutically acceptable means, by either systemic or local administration. Suitable modes of administration include oral, dermal, e. g., via transdermal patch, inhalation, via infusion, intranasal, rectal, vaginal, topical parenteral (e. g., via intraperitoneal, intravenous, intramuscular, subcutaneous, injection).

Typically, oral administration or administration via injection is preferred. The subject compounds may be administered in a single dosage or chronically dependent upon the particular disease, condition of patient, toxicity of compound, and whether this compound is being utilized alone or in combination with other therapies. Chronic or repeated administration will likely be preferred based on other chemotherapies.

The subject compounds will be administered in a pharmaceutically acceptable formulation or composition. Examples of such formulations include injectable solutions, tablets, milk, or suspensions, creams, oil-in-water and water-in-oil emulsions, microcapsules and microvesicles.

These compositions will comprise conventional pharmaceutical excipients and carriers typically used in drug formulations, e. g., water, saline solutions, such as phosphate buffered saline, buffers, surfactants.

The subject compounds may be free or entrapped in microcapsules, in colloidal drug delivery systems such as liposomes, microemulsions, and macroemulsions. Suitable materials and methods for preparing pharmaceutical formulations are disclosed in Remington's Pharmaceutical Chemistry, 16t Edition, (1980). Also, solid formulations containing the subject compounds, such as tablets, and capsule formulations, may be prepared.

Suitable examples thereof include semipermeable materials of solid hydrophobic polymers containing the subject compound which may be in the form of shaped articles, e. g., films or microcapsules, as well as various other polymers and copolymers known in the art.

The dosage effective amount of compounds according to the invention will vary depending upon factors including the particular compound, toxicity, and inhibitory activity, the condition treated, and whether the compound is administered alone or with other therapies. Typically a dosage effective amount will range from about 0.0001 mg/kg to 1500 mg/kg, more preferably 1 to 1000 mg/kg, more preferably from about 1 to 150 mg/kg of body weight, and most preferably about 50 to 100 mg/kg of body weight.

The subjects treated will typically comprise mammals and most preferably will be human subjects, e. g., human cancer subjects.

The compounds of the invention may be used alone or in combination.

Additionally, the treated compounds may be utilized with other types of treatments, e. g., cancer treatments. For example, the subject compounds may be used with other chemotherapies, e. g., tamoxifen, taxol, methothrexate, biologicals, such as antibodies, growth factors, lymphokines, or radiation, etc. Combination therapies may result in synergistic results. In particular, the compounds may be advantageously used in conjunction with herceptin based therapies.

The preferred indication is cancer, especially the cancers identified previously While the invention has been described in terms of preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.